Acute lymphoblastic leukemia with Philadelphia chromosome: Treatment with kinase inhibitors;Leucémie aiguë lymphoblastique à chromosome Philadelphie: Traitement par les inhibiteurs de kinases

Bulletin du Cancer

Volumn 94, Issue 10, 2007, Pages 871-880

  Thomas, Xavier ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Acute lymphoblastic leukemia; Bcr Abl; Dasatinib; Imatinib; Mutations; Nilotinib; Philadelphia chromosome; Resistance

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ADAPHOSTIN; AP 23573; AP 23576; BOSUTINIB; CC 1779; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DORAMAPIMOD; EVEROLIMUS; IMATINIB; LAP 23573; LONAFARNIB; NILOTINIB; PHOSPHOTRANSFERASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; VORINOSTAT; WORTMANNIN;

ACUTE LYMPHOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER RISK; GENE MUTATION; HUMAN; MULTIPLE CYCLE TREATMENT; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; REVIEW; TREATMENT OUTCOME;

ALKYL AND ARYL TRANSFERASES; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; INDOLES; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; PYRROLES; THIAZOLES;

EID: 36248953960     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0474     Document Type: Review

References (115)

1. Thomas X, Le QH. Stratégies thérapeutiques actuelles dans les leucémies aiguës lymphoblastiques de l'adulte. Bull Cancer 2003 ; 90 : 833-50.
2. Thomas X, Tavernier E, Le QH. Leucémie aiguë lymphoblastique du sujet âgé : pronostic et traitement. Bull Cancer 2004 ; 91 : 713-20.
3. Charrin C, Thomas X, Ffrench M, Le QH, Andrieux J, Mozziconacci MJ, et al. A report of the LALA-94 and LALA-SA groups on hypodiploidy with 30 to 39 chromosomes and near-triploidy : 2 possible expressions of a sole entity conferring poor prognosis in adult acute lymphoblastic leukemia (ALL). Blood 2004 ; 104 : 2444-51.
4. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults : age distribution, BCR breakpoint and prognostic significance. Leukemia 1991 ; 5 : 196-9.
5. Preti A, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM. Philadelphia-chromosome-positive adult acute lymphocytic leukemia : characteristics, treatment results, and prognosis in 41 patients. Am J Med 1994 ; 97 : 60-5.
6. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984 ; 37 : 1035-42.
7. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990 ; 247 : 1079-82.
8. Li S, Ilaria Jr. RL, Million RP, Daley GO, Van Etten RA. The P190, P210, and P230 forms in the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999 ; 189 : 1399-412.
9. Cimino G, Pano F, Elia L, Finolezzi E, Fazi P, Annino L, et al. The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia : a seven-year update of the Gimema 0496 trial. Haematologica 2006 ; 91 : 37-80.
10. Rieder H, Ludwig WD, Gassmann W, Maurer J, Janssen JWG, Gökbuget N, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1996 ; 95 : 678-91.
11. Goga A, McLaughlin J, Afar DA, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 1995 ; 82 : 981-8.
12. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. BCR-ABL-induced oncogeneis is mediated by direct interaction with the SH2 domain oftheGRB-2 adaptor protein. Cell 1993 ; 75 : 175-85.
13. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994 ; 13 : 764-73.
14. Skorski T, Nieborowska-Skorska M, Szczylik C, Kanakaraj P, Perrotti D, Zon G, et al. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res 1995 ; 55 : 2275-8.
15. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med 1995 ; 181 : 307-13.
16. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA 1995 ; 92 : 11746-50.
17. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996 ; 183 : 811-20.
18. Ilaria Jr. RL, van Etten RA. P210 and P190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996 ; 271 : 31704-10.
19. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E, et al. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998 ; 91 : 2415-22.
20. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Balwin AS. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev 1998 ; 12 : 968-81.
21. Cortez D, Stoica G, Pierce JH, Pendergast AM. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a ras-dependent signaling pathway. Oncogene 1996 ; 13 : 2589-94.
22. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 1995 ; 92 : 5287-91.
23. Skorski T, kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ARL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995 ; 86 : 726-36.
24. Salomoni P, Wasik MA, Riedel RF, Reiss K, Choi JK, Skorski T, et al. Expression of constitutively active Raf-1 in the mitochondria restores anti-apoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J Exp Med 1998 ; 187 : 1995-2007.
25. Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA, et al. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest 1997 ; 100 : 46-57.
26. Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1 alpha. Blood 1999 ; 94 : 4233-46.
27. Bazzoni G, Carlesso N, Griffin JD, Hemler ME. Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest 1996 ; 98 : 521-8.
28. Skorski T, Wlodarski P, Daheron L, Salomoni P, Nieborowska-Skorska M, Majewski M, et al. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Proc Natl Acad Sci USA 1998 ; 95 : 11858-62.
29. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW, et al. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood 1994 ; 84 : 2912-8.
30. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992 ; 70 : 901-10.
31. Afar DE, McLaughlin J, Sherr CJ, Witte ON, Roussel MF. Signaling by ABL oncogenes through cyclin D1. Proc Natl Acad Sci USA 1995 ; 92 : 9540-4.
32. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996 ; 2 : 561-6.
33. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000 ; 18 : 547-61.
34. Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood 2002 ; 100 : 2357-66.
35. Westbrook CA, Hooberman AL, Spino C, Dodge RK, Larson RA, Davey F, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia : A Cancer and Leukemia Group B study (8762). Blood 1992 ; 80 : 2983-90.
36. Götz G, Weh HJ, Walter TA, Kuse R, Kolbe K, Dolken G, et al. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol 1992 ; 64 : 97-100.
37. Mandelli F, Annino L, Ciolli S, Fabbiano F, Fanin R, Fioritoni G, et al. Philadelphia chromosome (Ph1) positive acute lymphoblastic leukemia (ALL) in adults : Interim results of Gimema ALL 0288 pilot study. Blood 1993 ; 82(suppl. 1) : 58a.
38. Annino L, Ferrari A, Cedrone M, Giona F, Lo Coco F, Meloni G, et al. Adult Philadelphia-chromosome-positive acute lymphoblastic leukemia : Experience of treatments during a ten-year period. Leukemia 1994 ; 8 : 664-7.
39. Thomas X, Thiebaut A, Olteanu N, Danaïla C, Charrin C, Archimbaud E, et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia : characteristics, prognostic factors and treatment outcome. Hematol Cell Ther 1998 ; 40 : 119-28.
40. Avivi I, Goldstone AH. Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplant 2003 ; 31 : 623-32.
41. Houot R, Tavernier E, Le QH, Lhéritier V, Thiebaut A, Thomas X. Philadelphia chromosome-positive acute lymphoblastic leukemia in the elderly : prognostic factors and treatment outcome. Hematology (Am Soc Hematol Educ Program) 2004 ; 9 : 369-76.
42. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, et al. Crystal structure of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002 ; 62 : 4236-43.
43. Beran M, Cao X, Estrov Z, Jeha S, Jin G, O'Brien S, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing M, 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998 ; 4 : 1661-72.
44. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001 ; 344 : 1038-42.
45. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, et al. A Phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002 ; 100 : 1965-71.
46. + ALL) treated with imatinib mesylate (Glivec). Blood 2004 ; 103 : 1495-8.
47. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006 ; 354 : 2531-41.
48. Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003 ; 17 : 1707-12.
49. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004 ; 103 : 4396-407.
50. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, et al. Update of the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia. Blood 2004 ; 104(suppl. 1) : 748a-9a.
51. De Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia : results of the GRAAPH-2003 study. Blood 2007 ; 109 : 1408-13.
52. Wassmann B, Pfeifer H, Gökbuger N, Beelen DW, Beck J, Stelljes M, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2006 ; 108 : 1469-77.
53. Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004 ; 104 : 3507-35.
54. Yanada M, Takeuchi J, Sigiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia : a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006 ; 24 : 460-6.
55. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005 ; 105 : 3449-57.
56. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondi F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia-positive patients with acute lymphoblastic leukemia without additional chemotherapy : results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007 ; 109 : 3076-8.
57. Pfeifer H, Wassmann B, Hoffmann WK, Komor M, Scheuring U, Bruch P, et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome positive acute leukemias treared with imatinib mesylate (Glivec). Clin Cancer Res 2003 ; 9 : 4674-81.
58. Delannoy A, Delabesse E, Lhéritier V, Castaigne S, Rigal-Huguet F, Raffoux E, et al. Imatinib and mcthylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia : results oi the GRALL AFR09 study. Leukemia 2006 ; 20 : 1526-32.
59. Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Duhrsen U, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer 2001 ; 109 : 2008-76.
60. Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 2007 ; 109 : 2791-3.
61. Daub H, Specht K, Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 2004 ; 3 : 1001-10.
62. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002 ; 99 : 3472-5.
63. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of philadelphia-positive patients. GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006 ; 12 : 7374-9.
64. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001 ; 293 : 876-80.
65. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003 ; 101 : 690-8.
66. Gambacorti-Passerini C, Barni R, Le Coutre P, Zuccheti M, Cabrita G, Cleris L, et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000 ; 92 : 1641-50.
67. IIlmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, Von Bonin M, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004 ; 18 : 401-8.
68. Golemovic M, Giles FJ, Beran M, Cortes J, Manshouri T, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, has preclinical activity against imatinib mesylate-resistant chronic myeloid leukemia (CML). Blood 2004 ; 104(suppl. 1) : 547a.
69. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004 ; 305 : 399-401.
70. Lombardo LJ, Lee FY, Chen P, Norris D, Barrisch JC, Behnia K, et al. Discovery of N- (2-chloro-6-methyl-phenyl)-2- (6- (4- (2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004 ; 47 : 6658-61.
71. O'Hare T, Walters DK, Stoffregen FP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005 ; 65 : 4500-5.
72. Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci USA 2005 ; 102 : 1992-7.
73. Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006 ; 108 : 645-52.
74. Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2006 ; 12 : 5869-78.
75. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, et al. Inhibition of drug-resistant mutants ot ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005 ; 102 : 11011-6.
76. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005 ; 7 : 129-11.
77. Von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006 ; 108 : 1328-33.
78. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006 ; 94 : 1765-9.
79. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 ; 354 : 2542-51.
80. Le Coutre P, Ottmann O, Gatterman N, Larson R, Rafferty T, Alland L, et al. A phase II study of Nilotinib (AMN107), a novel inhibitor of Bcr-Abl, administered to imatinib resistant patients and intolerant patients with chronic myeloid leukemia in accelerated phase (AP). J Clin Oncol 2006 ; 24 : 344s.
81. Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not cronic myeloid leukemia. Nat Genet 2004 ; 36 : 453-61.
82. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE, et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002 ; 21 : 5766-74.
83. Tobarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006 ; 66 : 5790-7.
84. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007 ; 92 : 401-4.
85. Sawyers CL, Shah NP, Kanterjian HM, Donato N, Nicoll J, Bai SA, et al. Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825 : results from a phase I dose escalation study. Blood 2004 ; 104(suppl. 1) : 4a.
86. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistance or - intolerant chronic myeloid leukemia in blast crisis. Blood 2001 ; 109 : 3207-13.
87. Coutre S, Martinelli G, Dombret H, Hochhaus A, Larson R, Saglio G, et al. Dasatinib in patients with chronic myeloid leukemia in lymphoid blast crisis or Philadelphia chromosome positive acute lymphoblastic leukemia who are imatinib resistant or intolerant : results of the «START-L» study. J Clin Oncol 2006 ; 24 : 344s.
88. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007 ; 109 : 2303-9.
89. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib : a randomized phase-II trial. Blood 2007 ; [Epub ahead of print].
90. Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib : interim results of a Phase II study. Blood 2001 ; [Epub ahead of print].
91. Bischoff JR, Plowman GD. The aurora/Ip11p kinase family : regulators of chromosome segregation and cytokinesis. Trends Cell Biol 1999 ; 9 : 454-9.
92. Giet R, Prigent C. Aurora/Ip11p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. J Cell Sci 1999 ; 112 : 3591-601.
93. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nature 2001 ; 2 : 21-32.
94. Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 2001 ; 11 : 49-54.
95. Kimura M, Matsuda Y, Yoshioda T, Okano Y. Cell cycle-dependent expression and centrosome localization of a third human aurora/Ip11p-related protein kinase, AIK3. J Biol Chem 1999 ; 274 : 7334-40.
96. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, Biggs WH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006 ; 66 : 1007-14.
97. Giles FJ, Cortes JE, Jones D, Bergstrom D, Kantarjian H, Freedman SJ. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007 ; 109 : 500-2.
98. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, et al. Clinical and biologic activity of the farnesyl transferase inhibitor R115777 in adults with refractory and relapsed acute leukemias : a phase 1 clinical-laboratory correlative trial. Blood 2001 ; 97 : 3361-9.
99. Hoover RR, Mahon FX, Melo JV, Daley GO. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002 ; 100 : 1068-71.
100. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamacyn derivatives. Ann Oncol 2005 ; 16 : 525-37.
101. Zeng Z, Sarbassovdos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007 ; 109 : 3509-12.
102. Brown VI, Fang J, Alcom K, Barr R, Kim JM, Wasserman R, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003 ; 100 : 15113-8.
103. Metcalf CA, Bohacek R, Rozamus LW, Burns KD, Roses JB, Rivera VM, et al. Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy. Proc Am Assoc Cancer Res 2004 ; 45 : 573.
104. Rivera VM, Tang H, Metcalf CA, Keenan TP, Sundaramoorthi R, Liu S, et al. Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents. Proc Am Assoc Cancer Res 2004 ; 45 : 896.
105. Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006 ; 17 : 487-94.
106. Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs 2003 ; 4 : 757-63.
107. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005 ; 280 : 35217-27.
108. Lierman E, Folens C, Stover EH, Mentens N, van Miegroet H, Scheers W, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006 ; 108 : 1374-6.
109. Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007 ; 21 : 439-45.
110. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, et al. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro : induction of apoptosis through Akt and c-jun NH2-terminal kinase pathways. Mol Cancer Ther 2006 ; 5 : 2378-87.
111. Chow LQM, Eckhardt SG. Sunitinib : from rational design to clinical efficacy. J Clin Oncol 2007 ; 25 : 884-96.
112. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006 ; 24 : 25-35.
113. O'Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003 ; 9 : 5465-76.
114. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrel-l AM, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to onventional therapy for the disease. Blood 2005 ; 105 : 986-93.
115. Yee KW, Schittenhelm M, O'Farrell M, Town AR, McGreevey L, Bainbridge T, et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004 ; 104 : 4202-9.